Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.67 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.67 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.51 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28339849 | 0.86 | ALDH1A1 (0.49) | L3MBTL3L3MBTL1MBTD1TP53BP1GRIN2B | |
| SCHEMBL541280 | 0.84 | L3MBTL1 (0.41) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL160644 | 0.82 | PRMT6 (0.42) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL12498579 | 0.81 | HDAC4 (0.46) | L3MBTL3L3MBTL1MBTD1HDAC4GRIN2B | |
| SCHEMBL13033990 | 0.80 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3606736 | 0.80 | L3MBTL1 (0.37) | L3MBTL3L3MBTL1MBTD1GRIN2B | |
| SCHEMBL27896079 | 0.79 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL23682775 | 0.78 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL26113263 | 0.78 | KHK (0.43) | L3MBTL3L3MBTL1MBTD1GRIN2B | |
| SCHEMBL4041212 | 0.77 | L3MBTL3 (0.75) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | claimed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| CN-103429079-A | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION INC | 2013-12-04 | — | — | CN | claimed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| EP-1165505-B1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LAB (US) | 2004-09-08 | — | — | EP | claimed |
| CN-110467638-A | A kind of double amino Chloropyrimide class compounds containing m-chloroaniline class substituent group, preparation method and applications | BEIJING SAITE MINGQIANG MEDICINE TECH CO LTD | 2019-11-19 | — | — | CN | disclosed |
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| CN-103429079-A | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION INC | 2013-12-04 | — | — | CN | disclosed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-1165505-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059880-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | L3MBTL3 4045/4885L3MBTL1 3578/4885MBTD1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.